Top

Published in:

01-10-2016 | Original Paper

Plasma adropin level in patients with pseudoexfoliation

Authors: Tevfik Oğurel, Reyhan Oğurel, Mustafa Topuz, Nurgül Örnek, Kemal Örnek

Published in: International Ophthalmology | Issue 5/2016

Abstract

The aim of this study was to evaluate plasma adropin levels in patients with pseudoexfoliation (PEX). This retrospective case–control study included 35 patients with PEX and 35 individuals without PEX who served as controls. Plasma adropin levels with triglycerides, total cholesterol, low-density lipoprotein (LDL), high-density lipoprotein (HDL), and haemoglobin A1c (HGBA1C) concentrations were measured in both groups. The mean serum adropin levels were 3.24 ± 0.95 ng/mL (range, 1.90–7.88 ng/mL) in patients with PEX syndrome and 5.78 ± 2.85 ng/mL (range, 2.08–5.41 ng/mL) in PEX glaucoma patients. There was no statistically significant difference in mean adropin levels between PEX syndrome and PEX glaucoma patients. However, similar adropin levels were found in the PEX glaucoma patients and the control group (P > 0.05). The mean serum adropin levels were 3.34 ± 0.89 ng/mL (range, 1.90–5.39 ng/mL) in the PEX group and 5.78 ± 2.85 ng/mL (range, 3.08–11.06 ng/mL) in the control group. The mean serum adropin level of the PEX group was significantly lower than that of the control group (P < 0.001). There were no significant differences between the two groups in terms of serum glucose, total cholesterol, LDL, HDL, HGBA1C, triglycerides levels, or body mass index (all P > 0.05). Adropin level is lower in patients with PEX.

Ritch R, Schlotzer-Schrehardt U (2001) Exfoliation syndrome. Surv Ophthalmol 45:265–315CrossRefPubMed

Hewitt AW, Sharma S, Burdon KP, Wang JJ, Baird PN, Dimasi DP et al (2008) Ancestral LOXL1 variants are associated with pseudoexfoliation in Caucasian Australians but with markedly lower penetrance than in Nordic people. Hum Mol Genet 17:710–716CrossRefPubMed

Amari F, Umihira J, Nohara M et al (1997) Electron microscopic immunohistochemistry of ocular and extraocular pseudoexfoliative material. Exp Eye Res 65:51–56CrossRefPubMed

Schlötzer- Schrehardt UM, Koca MR, Naumann GO, Volkholz H (1992) Pseudoexfoliation syndrome ocular manifestation of a systemic disorder? Arch Ophthalmol 110(12):1752–1756CrossRefPubMed

Mitchell P, Wang JJ, Smith W (1997) Association of pseudoexfoliation syndrome with increased vascular risk. Am J Ophthalmol 124:685–687CrossRefPubMed

Shrum KR, Hattenhauer MG, Hodge D (2000) Cardiovascular and cerebrovascular mortality associated with ocular pseudoexfoliation. Am J Ophthalmol 129:83–86CrossRefPubMed

Naji M, Naji F, Suran D, Gracner T, Kanic V, Pahor D (2008) Systemic endothelial dysfunction in patients with pseudoexfoliation syndrome. Klin Monbl Augenheilkd 225(11):963–967CrossRefPubMed

Kumar KG, Trevaskis JL, Lam DD et al (2008) Identification of adropin as a secreted factor linking dietary macronutrient intake with energy homeostasis and lipid metabolism. Cell Metab 8:468–481CrossRefPubMedPubMedCentral

Lovren F, Pan Y, Quan A et al (2010) Adropin is a novel regulator of endothelial function. Circulation 122:185–192CrossRef

10.

Lian W, Gu X, Qin Y, Zheng X (2011) Elevated plasma levels of adropin in heart failure patients. Intern Med 50(15):1523–1527CrossRefPubMed

11.

Celik A, Balin M, Kobat MA et al (2013) Deficiency of a new protein associated with cardiac syndrome X; called adropin. Cardiovasc Ther 31(3):174–178CrossRefPubMed

12.

Aydin S (2015) A short history, principles, and types of ELISA, and our laboratory experience with peptide/protein analyses using ELISA. Peptides 72:4–15CrossRefPubMed

13.

Praveen MR, Shah SK, Vasavada AR et al (2011) Pseudoexfoliation as a risk factor for peripheral vascular disease: a case-control study. Eye 25:174–179CrossRefPubMed

14.

Schlötzer-Schrehardt U, Naumann GO (2006) Ocular and systemic pseudoexfoliation syndrome. Am J Ophthalmol 141(5):921–937CrossRefPubMed

15.

Ovodenko B, Rostagno A, Neubert TA et al (2007) Proteomic analysis of exfoliation deposits. Invest Ophthalmol Vis Sci 48:1447–1457CrossRefPubMed

16.

Streenten BW, Li ZY, Wallace RN, Eagle RC Jr, Keshgegian AA (1992) Pseudoexfoliative fibrillopathy in visceral organs of a patient with pseudoexfoliation syndrome. Arch Ophthalmol 110:1757–1762CrossRef

17.

Mitchell P, Wang JJ, Smith W (1997) Association of pseudoexfoliation syndrome with increased vascular risk. Am J Ophthalmol 124:685–687CrossRefPubMed

18.

Shrum KR, Hattenhauer MG, Hodge D (2000) Cardiovascular and cerebro-vascular mortality associated with ocular pseudoexfoliation. Am J Ophthalmol 129:83–86CrossRefPubMed

19.

Atalar PT, Atalar E, Kilic H et al (2006) Impaired systemic endothelial function in patients with pseudoexfoliation syndrome. Int Heart J 47:77–84CrossRefPubMed

20.

Citirik M, Acaroglu G, Batman C, Yildiran L, Zilelioglu O (2007) A possible link between the pseudoexfoliation syndrome and coronary artery disease. Eye 21:11–15CrossRefPubMed

21.

French DD, Margo CE, Harman LE (2012) Ocular pseudoexfoliation and cardiovascular disease: a national cross-section comparison study. N Am J Med Sci 4:468–473CrossRefPubMedPubMedCentral

22.

Tosun M, Simavli H, Önder HI, Erdurmus M (2014) Serum levels of omentin in pseudoexfoliation syndrome. J Glaucoma. doi:10.1097/IJG.0000000000000139

23.

Türkyılmaz K, Öner V, Kırbas A, Sevim MS, Sekeryapan B, Özgür G, Durmus M (2013) Serum ykl-40 levels as a novel marker of inflammation and endothelial dysfunction in patients with pseudoexfoliation syndrome. Eye 27(7):854–859CrossRefPubMedPubMedCentral

24.

Zhou JY, Chan L, Zhou SW (2014) Omentin: linking metabolic syndrome and cardiovascular disease. Curr Vasc Pharmacol 12:136–143CrossRefPubMed

25.

Topuz M, Celik A, Aslantas T, Demir AK, Aydin S, Aydin S (2013) Plasma adropin levels predict endothelial dysfunction like flow-mediated dilatation in patients with type 2 diabetes mellitus. J Investig Med 61(8):1161–1164CrossRefPubMed

26.

27.

Celik A, Balin M, Kobat MA et al (2013) Deficiency of a new protein associated with cardiac syndrome X; called adropin. Cardiovasc Ther 31(3):174–178CrossRefPubMed

28.

Zhang C, Zhao L, Xu W, Li J, Wang B, Gu X, Chen J (2014) Correlation of serum adropin level with coronary artery disease. Zhonghua Yi Xue Za Zhi 94:1255–1257PubMed

Title: Plasma adropin level in patients with pseudoexfoliation
Authors: Tevfik Oğurel
Reyhan Oğurel
Mustafa Topuz
Nurgül Örnek
Kemal Örnek
Publication date: 01-10-2016
Publisher: Springer Netherlands
Published in: International Ophthalmology / Issue 5/2016
Print ISSN: 0165-5701
Electronic ISSN: 1573-2630
DOI: https://doi.org/10.1007/s10792-016-0185-8

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Plasma adropin level in patients with pseudoexfoliation

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2016

Evaluation of the long-term results of trabectome surgery

Expression of a hyaluronic acid-binding proteoglycan (versican) in the cynomolgus monkey eye

A very rare case of eyelid metastasis originating from lung adenocarcinoma

Comparison of histopathological findings between idiopathic and secondary epiretinal membranes

New insights in diagnosis and treatment for Retinopathy of Prematurity

Clinical outcomes of trabeculectomy versus Ahmed glaucoma valve implantation in patients with penetrating keratoplasty